Selected article for: "cell type and stem cell"
Author: Cho, Sung-Yeon; Lee, Hyeon-Jeong; Lee, Dong-Gun
Title: Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea
  • Cord-id: t9tysvr8
  • Document date: 2018_2_27
    • ID: t9tysvr8
    Snippet: Hematopoietic stem cell transplantation (HSCT) is a treatment for hematologic malignancies, immune deficiencies, or genetic diseases, ect. Recently, the number of HSCTs performed in Korea has increased and the outcomes have improved. However, infectious complications account for most of the morbidity and mortality after HSCT. Post-HSCT infectious complications are usually classified according to the time after HSCT: pre-engraftment, immediate post-engraftment, and late post-engraftment period. I
    Document: Hematopoietic stem cell transplantation (HSCT) is a treatment for hematologic malignancies, immune deficiencies, or genetic diseases, ect. Recently, the number of HSCTs performed in Korea has increased and the outcomes have improved. However, infectious complications account for most of the morbidity and mortality after HSCT. Post-HSCT infectious complications are usually classified according to the time after HSCT: pre-engraftment, immediate post-engraftment, and late post-engraftment period. In addition, the types and risk factors of infectious complications differ according to the stem cell source, donor type, conditioning intensity, region, prophylaxis strategy, and comorbidities, such as graft-versushost disease and invasive fungal infection. In this review, we summarize infectious complications after HSCT, focusing on the Korean perspectives.

    Search related documents:
    Co phrase search for related documents
    • long term hospitalization and lymphocyte count: 1
    • long term immunosuppressive therapy and low culture positive rate: 1
    • long term immunosuppressive therapy and low voriconazole: 1
    • long term immunosuppressive therapy and low voriconazole concentration: 1
    • long term immunosuppressive therapy and lung biopsy: 1
    • lung tissue and lymphocyte count: 1, 2